Press Release

For Immediate Release

Yicura Debuts Encouraging ICVAX IIT Results at BIO 2026

Concurrently Signs MOU with OPIS to Accelerate Global Clinical Development

(Hong Kong, July 13, 2026) – Yicura BioMed ("**Yicura**"), formerly known as Immuno Cure BioTech, is pleased to announce the first global public release of encouraging results from the Investigator-Initiated Trial ("**IIT**") of ICVAX, its therapeutic DNA vaccine aiming for functional cure of HIV infection. Unveiled at the BIO International Convention 2026 ("**BIO 2026**") in San Diego, USA, this milestone marks Yicura's first clinical study presentation on a major world stage, capturing the attention of a global audience with biotech and pharmaceutical backgrounds from more than 70 countries.

***Dr. Xia JIN**, Co-founder and CEO of Yicura, publicly presented the encouraging results of the ICVAX IIT at BIO 2026.*

Despite modern advances in prevention and treatment, HIV/AIDS continues to be a formidable global health challenge. By 2025, the population of individuals living with HIV exceeded 40 million, with cumulative fatalities surpassing 43 million since the epidemic first emerged in 1981. While contemporary antiretroviral therapy ("**ART**")

successfully controls viral loads in HIV-1 positive individuals, it remains a lifelong management tool rather than a definitive cure. This gap highlights the urgent need for innovative immunotherapies capable of boosting the host immune response to achieve sustained, ART-free viral control, ultimately delivering a functional cure of HIV infection.

The IIT was conducted as an extension of the previously completed Phase I clinical trial of ICVAX, a HIV-1 therapeutic DNA vaccine developed based on the PD-1-enhanced DNA vaccine technology, which demonstrated favorable safety profile and potent immunogenicity. Ten ART-suppressed, HIV-1-positive participants who had previously completed ICVAX dosing in the Phase I trial were enrolled. Each participant underwent two cycles of the following treatment: a booster dose of ICVAX, followed by a 24-week analytical treatment interruption (ATI), a monitored pause in ART, beginning two weeks after ICVAX dosing. This created two sequential “ICVAX + ATI” cycles. The primary objectives were to assess the safety and the efficacy of the regimen at Week 52, by the end of the second ATI cycle.

In the first ATI, one of the ten participants (10%) sustained complete viral suppression off ART, while the other nine showed viral rebound and resumed ART. Seven participants met protocol criteria to advance to the second cycle of ICVAX dosing and ATI. There, two of the seven participants (28.6%) achieved off-ART control by Week 42. The majority of participants showed slower viral rebound kinetics in the second cycle than in the first, indicating improved viral control after the second cycle of ICVAX dosing and ATI. Most notably, one participant (14%) sustained complete viral suppression and has remained off ART for one year throughout the whole study period, demonstrating durable ART-free control of HIV-1. These preliminary findings provide early clinical evidence supporting the potential of ICVAX to advance toward a functional cure for HIV-1.

In another key development at BIO 2026, Yicura officially signed a Memorandum of Understanding (“**MOU**”) with OPIS S.r.l. (“**OPIS**”) to accelerate the clinical development of ICVAX in the U.S. and Europe. Building on the momentum of Yicura's concurrent IIT data release, this strategic collaboration leverages OPIS’s extensive multi-country trial management and international regulatory expertise. It positions Yicura to streamline its global clinical development pathways and advance its regulatory strategies with key authorities, including the U.S. FDA and the EMA, bringing this HIV functional cure candidate one step closer to global markets.

From left to right: ***Dr. Xia JIN****, CEO and Co-Founder of Yicura;* ***Mr. Giovanni Trolese****, Vice President of OPIS.*

Dr. Xia JIN, CEO of Yicura stated, “Signing this MOU with OPIS at BIO 2026 is a pivotal step in expanding our global clinical footprint. As we prepare to advance ICVAX into the U.S. and European markets, OPIS’s robust international regulatory and trial management expertise will be invaluable. We anticipate this collaboration will significantly accelerate our development timelines, bringing us closer to delivering a much-needed therapeutic strategy to HIV patients worldwide.”

Mr. Giovanni Trolese, Vice President of OPIS, remarked, “We are delighted to partner with Yicura to support the global development of ICVAX. Addressing the critical unmet need for an HIV functional cure aligns perfectly with our clinical mission, and OPIS is eager to deploy our international regulatory and multi-country trial expertise across the U.S. and Europe. We look forward to a highly productive collaboration that efficiently guides ICVAX through its upcoming clinical milestones.”

###

About Yicura (formerly Immuno Cure)

Yicura is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody platforms.

To learn more about Yicura, please visit: www.yicura.hk

About BIO International Convention

The BIO International Convention is the largest biotechnology event, bringing together 20,000 industry leaders from across the global biotech ecosystem. BIO 2026 offers a platform for the community to reconnect and focus on the shared mission of improving lives through innovation. Attendees include pharmaceutical companies, biotech startups, academia, non-profits, government agencies, researchers, business development professionals, and investors.

To learn more about BIO International Convention, please visit: https://convention.bio.org/

About OPIS

OPIS is a full-service Contract Research Organization (CRO) founded in 1998 in Italy, providing trial management for multi-country clinical trials, including information technology solutions and adaptive approaches designed to address project complexity. OPIS operates across all phases of drug related trials, a broad range of therapeutic areas as well as clinical investigations for medical and diagnostic devices, IITs, and compassionate use programs.

To learn more about OPIS, please visit: https://opisresearch.com/

For media enquiries, please contact:

Yicura

Ms. Carol CHUNG

Email: carolchung@yicura.hk

Yicura

Dr. Anthony CHEUNG

Email: anthonycheung@yicura.hk